Volume 9, Number 1—January 2003
Research
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Table 2
Intermediate health outcomes of HPV vaccinationa,b
Outcome | HPV vaccination | No vaccination | Lifetime cases averted | No. needed to vaccinate to prevent one case |
---|---|---|---|---|
HPV | 1,460,699 | 1,684,954 | 224,255 | 9 |
SIL | 417,549 | 530,259 | 112,710 | 18 |
Cervical cancer | 13,374 | 16,690 | 3,316 | 600 |
Cervical-cancer deaths | 5,121 | 6,461 | 1,340 | 1,484 |
aAssumes program that successfully administers a vaccine against high-risk HPV to the current U.S. cohort of 12-year-old girls.
bHPV, Human papillomavirus; SIL, squamous intraepithelial lesions.